menu
    • menu
    [{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Tiumbio","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Merigolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daewon Pharm. Co., Ltd \/ Daewon Pharm. Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Daewon Pharm. Co., Ltd \/ Daewon Pharm. Co., Ltd"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Daewon Pharm. Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Choline Fenofibrate","moa":"||Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Daewon Pharm. Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Daewon Pharm. Co., Ltd \/ Daewon Pharm. Co., Ltd"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"||anti-inflammatory\/analgesic agents (ibuprofen type)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ezetimibe","moa":"||Niemann-Pick C1-like protein 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"DWKH","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DW1601","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DW1903","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DW1903","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DW1809","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DW1809-1","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DW5221","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewon Pharm. Co., Ltd \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Daewon Pharm. Co., Ltd

    Menu

    Daewon Pharm. Co., Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Merigolix,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Recipient : Tiumbio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TiumBio and Daewon Complete Phase 2 Merigolix Trial for Fibroids

                            Details : TU2670 (merigolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist, being investigated for uterine fibroids.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 07, 2025

                            Lead Product(s) : Merigolix,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Recipient : Tiumbio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DW5221,DW5221-R

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 28, 2023

                            Lead Product(s) : DW5221,DW5221-R

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ezetimibe,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 01, 2023

                            Lead Product(s) : Ezetimibe,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DWKH,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Efficacy and Safety of DWKH

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 13, 2023

                            Lead Product(s) : DWKH,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Choline Fenofibrate,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Recipient : Seoul National University Bundang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 09, 2022

                            Lead Product(s) : Choline Fenofibrate,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Recipient : Seoul National University Bundang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DW1809,DW1809-1

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 31, 2022

                            Lead Product(s) : DW1809,DW1809-1

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DW1809-T2,DW1809-1

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 31, 2022

                            Lead Product(s) : DW1809-T2,DW1809-1

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DW1903,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 20, 2021

                            Lead Product(s) : DW1903,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DW1903,DW1903-R1,DW1903-R2

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 13, 2021

                            Lead Product(s) : DW1903,DW1903-R1,DW1903-R2

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelubiprofen,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 09, 2020

                            Lead Product(s) : Pelubiprofen,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth